Perrigo Company plc $PRGO Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. grew its stake in Perrigo Company plc (NYSE:PRGO) by 6.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 61,717 shares of the company’s stock after buying an additional 3,981 shares during the quarter. D.A. Davidson & CO.’s holdings in Perrigo were worth $1,649,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. State of Michigan Retirement System lifted its stake in shares of Perrigo by 1.2% in the 1st quarter. State of Michigan Retirement System now owns 32,658 shares of the company’s stock valued at $916,000 after purchasing an additional 400 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in shares of Perrigo by 54.6% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock worth $32,000 after acquiring an additional 424 shares during the period. State of Alaska Department of Revenue raised its position in shares of Perrigo by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 15,984 shares of the company’s stock worth $448,000 after acquiring an additional 430 shares during the period. Amundi raised its position in shares of Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after acquiring an additional 556 shares during the period. Finally, Public Employees Retirement System of Ohio raised its holdings in Perrigo by 1.4% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 42,290 shares of the company’s stock worth $1,130,000 after purchasing an additional 564 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Insider Activity at Perrigo

In other news, EVP Abigail Lennox bought 1,255 shares of the company’s stock in a transaction on Monday, September 8th. The stock was bought at an average cost of $22.41 per share, with a total value of $28,124.55. Following the transaction, the executive vice president directly owned 1,255 shares in the company, valued at $28,124.55. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Willis acquired 1,488 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was acquired at an average price of $24.10 per share, with a total value of $35,860.80. Following the acquisition, the executive vice president directly owned 41,939 shares of the company’s stock, valued at approximately $1,010,729.90. This represents a 3.68% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 10,118 shares of company stock worth $232,699 over the last quarter. Company insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on PRGO. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a research note on Sunday. JPMorgan Chase & Co. reduced their price objective on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Canaccord Genuity Group reduced their price target on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Perrigo in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $34.00.

Perrigo Price Performance

Perrigo stock opened at $21.48 on Monday. The company has a 50-day moving average price of $22.26 and a 200 day moving average price of $24.82. The stock has a market cap of $2.95 billion, a P/E ratio of -37.03 and a beta of 0.43. The company has a current ratio of 2.32, a quick ratio of 1.24 and a debt-to-equity ratio of 0.81. Perrigo Company plc has a 12-month low of $20.51 and a 12-month high of $30.93.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.02). Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the business posted $0.53 earnings per share. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. Sell-side analysts anticipate that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 29th were issued a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 5.4%. The ex-dividend date was Friday, August 29th. Perrigo’s dividend payout ratio (DPR) is -200.00%.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.